ALSO READ: Corbevax approved as booster for those jabbed with Covishield, Covaxin: Report "This approval came after the Drug Controller General of India (DCGI) approved the vaccine for emergency use as a heterologous COVID-19 booster dose for individuals aged 18 years on June 4, 2022," an official statement from the BE said.
Apart from this, the Hyderabad-based pharmaceutical company said that the Corbevax had received emergency use authorization as a primary two-dose vaccination regimen in adults, adolescents and children aged 5 years and above, in a series of approvals from December'21 to April'22. "Pan-India roll-out of the booster shot vaccine in children aged between 12 to 14 years was initiated on March 16, 2022 and till now almost 7 crore doses have been administered and 2.9 crore children completed their two-dose vaccination regimen," it said.
The Corbevax manufacturer claims its vaccine has undergone comprehensive booster trials on Indian subjects and subsequently received approval from the Indian regulatory authority.
The Corbevax uses a traditional recombinant protein-based technology, which is also used for vaccines such as Hepatitis B. "Corbevax has become the first vaccine in India to be approved as a heterologous COVID-19 booster.